{"id":5296,"date":"2019-06-20T16:06:09","date_gmt":"2019-06-20T10:36:09","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5296"},"modified":"2021-07-24T12:57:24","modified_gmt":"2021-07-24T07:27:24","slug":"the-business-cocktail-gilead-sciences","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\"><strong>Gilead jumps into a competitive Protein degradation field, signs a USD 45 M Nurix deal<\/strong> <br><\/h4>\n\n\n\n<p><strong>Gilead Sciences<\/strong> is turning to <strong>Nurix Therapeutics <\/strong>for enhancing <a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancer <\/a>pipeline. Gilead is ready to pay<strong> USD 45 million <\/strong>upfront, and if all the targets are achieved the deal could reach up to USD 2.3 billion. <strong>Nurix <\/strong>is a drug developing company focused on operating the ubiquitin system, which breaks down damaged, unneeded and disease-causing proteins. The partnership will arm Nurix to use its technology to accelerate its drug discovery especially the ones that use <strong>E3 ligases<\/strong>\u2014enzymes that regulate protein levels in human cells and degrade specific protein targets. On the other hand, Gilead will have the option to license up to five different disease targets research programs related to cancer and other challenging diseases. The companies, however, will continue to build their relative pipeline individually. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Comet Therapeutics comes\nout of its stealth mode, raises USD 28.5 M<\/strong><\/h4>\n\n\n\n<p><strong>Comet Therapeutics<\/strong> has successfully raised <strong>USD 28.5 million<\/strong> in Series A funding to progress its research and drug development. The funding led by its existing investor<strong> Sofinnova Partners,<\/strong> and <strong>INKEF Capital<\/strong> along with a new investor, <strong>BioInnovation Capital.<\/strong> Comet\u2019s pipeline includes several potential therapies for metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. The funding subsidised to Comet will help in advancing its drug into the trials. The company also aims to develop a drug, through its <strong>Coenzyme A <\/strong>technology, to treat metabolic, neurological and immunological disorders.&nbsp;&nbsp;  <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Cara Care Nabs USD 7M&nbsp;IN A Series led by J&amp;J<\/strong><\/h4>\n\n\n\n<p>Germany-based&nbsp;digital health&nbsp;company&nbsp;<strong>Cara Care<\/strong>,&nbsp;announced today that it has secured USD 7 million in Series A funding primarily led by&nbsp;<strong>Johnson &amp; Johnson Innovation<\/strong> alongside with &nbsp;Barcelona-based VC firm Asabys Partners and existing investor Atlantic Labs. Cara care launched an app to offer patients struggling with <a href=\"https:\/\/www.delveinsight.com\/report-store\/irritable-bowel-syndrome-ibs-market-insight-epidemiology-and-market-forecast\">irritable bowel syndrome<\/a>, inflammatory bowel disease and <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastroparesis-market-insight-epidemiology-and-market-forecast\">gastrointestinal <\/a>reflux disease. The company developed the app to help them manage their medications and improve their diets. The ideology of the company is a belief in mobile software to treat GI diseases in a better way. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gilead jumps into a competitive Protein degradation field, signs a USD 45 M Nurix deal Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the targets are achieved the deal could reach up to USD 2.3 billion. Nurix is a drug [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5118,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[137,841],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-5296","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-cancer","tag-cancer-research","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Business Cocktail 20\/06\/2019 - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Business Cocktail 20\/06\/2019 - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-20T10:36:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The Business Cocktail 20\/06\/2019 - DelveInsight Business Research","description":"Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences","og_locale":"en_US","og_type":"article","og_title":"The Business Cocktail 20\/06\/2019 - DelveInsight Business Research","og_description":"Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the...","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-20T10:36:09+00:00","article_modified_time":"2021-07-24T07:27:24+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences","name":"The Business Cocktail 20\/06\/2019 - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","datePublished":"2019-06-20T10:36:09+00:00","dateModified":"2021-07-24T07:27:24+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead Sciences is turning to Nurix Therapeutics for enhancing cancer pipeline. Gilead is ready to pay USD 45 million upfront, and if all the...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-gilead-sciences#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may.png","width":647,"height":345,"caption":"Business cocktail"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/09021239\/Business-23-may-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 20, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 20, 2019 4:06 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Business cocktail","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5296"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5296\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5118"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5296"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5296"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}